Aptorum Group Granted The First Patent for its SACT-1 Repurposed Drug For Treatment of Various Cancer Including but Not Limited to Neuroblastoma
19 January 2022 - 12:00AM
Business Wire
Regulatory News:
Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM)
(“Aptorum Group” or “Aptorum”), a clinical-stage biopharmaceutical
company, is pleased to announce that the US Patent and Trademark
Office has granted the first patent regarding Aptorum’s SACT-1
repurposed drug for the treatment of various cancers including but
not limited to neuroblastoma (US Patent 11,166,962 B2).
The SACT-1 invention provides a composition and method for
treating or preventing the growth of cancerous tumors and/ or
delaying the onset of cancer from tumor-initiating cells. The
composition is administered alone or in combination with one or
more chemotherapeutic agents, biological agents, and/or anticancer
agents by various routes of administration and dosage forms.
Mr Darren Lui, President and Executive Director of Aptorum Group
says, “In addition to our previous announcement of the completion
of our Phase 1 clinical trial of SACT-1 on January 10, 2022, we are
pleased to have received the granted patent from the USPTO on our
drug candidate. As IP protection is critically important for
protecting our investment in developing repurposed drugs, the
granted patent will further support our ongoing development effort
of SACT-1 as a potentially effective treatment of neuroblastoma and
other cancer types. We will be actively seeking further IP
protection on our SACT-1 repurposed drug via patent applications in
major jurisdictions and the embarking of the exciting Phase Ib/2a
clinical trials for SACT-1, subject to IND clearance in 2022.”
About SACT-1
SACT-1 is an orally administered repurposed small molecule drug
to target neuroblastoma. SACT-1’s mechanism has been investigated
in our preclinical studies to enhance tumor cell death and suppress
MYCN expression (a common clinical diagnosis in high-risk or
relapsed neuroblastoma patients where an amplification of MYCN is
usually observed). SACT-1 is designed to be used especially in
combination with standard-of-care chemotherapy.
About Aptorum Group Limited
Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) is a
clinical stage biopharmaceutical company dedicated to the
discovery, development and commercialization of therapeutic assets
to treat diseases with unmet medical needs, particularly in
oncology (including orphan oncology indications) and infectious
diseases. The pipeline of Aptorum is also enriched through (i) the
establishment of drug discovery platforms that enable the discovery
of new therapeutics assets through, e.g. systematic screening of
existing approved drug molecules, and microbiome-based research
platform for treatments of metabolic diseases; and (ii) the
co-development of a novel molecular-based rapid pathogen
identification and detection diagnostics technology with Accelerate
Technologies Pte Ltd, commercialization arm of the Singapore’s
Agency for Science, Technology and Research.
For more information about Aptorum Group, please visit
www.aptorumgroup.com.
Disclaimer and Forward-Looking Statements
This press release does not constitute an offer to sell or a
solicitation of offers to buy any securities of Aptorum Group.
This press release includes statements concerning Aptorum Group
Limited and its future expectations, plans and prospects that
constitute “forward-looking statements” within the meaning of the
US Private Securities Litigation Reform Act of 1995. For this
purpose, any statements contained herein that are not statements of
historical fact may be deemed to be forward-looking statements. In
some cases, you can identify forward-looking statements by terms
such as “may,” “should,” “expects,” “plans,” “anticipates,”
“could,” “intends,” “target,” “projects,” “contemplates,”
“believes,” “estimates,” “predicts,” “potential,” or “continue,” or
the negative of these terms or other similar expressions. Aptorum
Group has based these forward-looking statements, which include
statements regarding projected timelines for application
submissions and trials, largely on its current expectations and
projections about future events and trends that it believes may
affect its business, financial condition and results of operations.
These forward-looking statements speak only as of the date of this
press release and are subject to a number of risks, uncertainties
and assumptions including, without limitation, risks related to its
announced management and organizational changes, the continued
service and availability of key personnel, its ability to expand
its product assortments by offering additional products for
additional consumer segments, development results, the company’s
anticipated growth strategies, anticipated trends and challenges in
its business, and its expectations regarding, and the stability of,
its supply chain, and the risks more fully described in Aptorum
Group’s Form 20-F and other filings that Aptorum Group may make
with the SEC in the future, as well as the prospectus that received
the French Autorité des Marchés Financiers visa n°20-352 on 16 July
2020. As a result, the projections included in such forward-looking
statements are subject to change and actual results may differ
materially from those described herein.
Aptorum Group assumes no obligation to update any
forward-looking statements contained in this press release as a
result of new information, future events or otherwise.
This announcement is not a prospectus within the meaning of the
Regulation (EU) n°2017/1129 of 14 June 2017 as amended by
Regulations Delegated (EU) n°2019/980 of 14 March 2019 and
n°2019/979 of 14 March 2019.
This press release is provided “as is” without any
representation or warranty of any kind.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220118005611/en/
Aptorum Group Limited Investor Relations Department
investor.relations@aptorumgroup.com +44 20 80929299
Redchip – Financial Communications United States Investor
relations Dave Gentry dave@redchip.com +1 407 491 4498
Actifin – Financial Communications Europe Investor relations
Ghislaine Gasparetto ggasparetto@actifin.fr +33 1 56 88 11 22
Aptorum (NASDAQ:APM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aptorum (NASDAQ:APM)
Historical Stock Chart
From Apr 2023 to Apr 2024